GXAI

Rocket Pharmaceuticals Update: Shares of Rocket Pharmaceuticals surged 15.8% in pre-market trading after the FDA lifted the clinical hold on their Phase 2 trial for RP-A501, aimed at treating Danon disease.

Pre-Market Stock Movements: Several stocks experienced significant changes in pre-market trading, including NovaBay Pharmaceuticals which rose 64.2%, and James Hardie Industries which fell 27% following disappointing quarterly results.

Notable Gainers: Other notable gainers included Propanc Biopharma (up 37.8%) and ScanTech AI Systems (up 36.4%), both benefiting from positive announcements regarding investments and collaborations.

Significant Losers: Stocks that saw declines included Cytosorbents Corporation (down 25.7%) due to regulatory updates, and La-Z-Boy Incorporated (down 22.2%) after reporting weaker-than-expected financial results.

U.S. Stock Market Performance: U.S. stocks declined, with the Nasdaq Composite dropping over 1.5%, while the Dow and S&P 500 also experienced losses.

Medtronic's Strong Earnings Report: Medtronic plc reported better-than-expected first-quarter earnings, with sales of $8.58 billion and adjusted earnings of $1.26 per share, leading to an increase in revenue growth guidance.

Notable Stock Movements: Plymouth Industrial REIT shares surged by 51% after an acquisition proposal, while Gaxos.ai Inc. and Laser Photonics Corporation saw significant gains, whereas Thumzup Media Corporation and Viking Therapeutics faced substantial declines.

Commodity and Global Market Trends: Oil and gold prices fell slightly, while European markets showed positive movement, contrasting with mostly lower Asian markets; U.S. housing starts increased by 5.2% in July.